Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.
Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.
Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.
Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its participation in the 37th Annual ROTH Conference. The event is scheduled for March 17-18 in Dana Point, California.
The company, which specializes in treatments for both oncological and non-oncological skin conditions, will be conducting one-on-one meetings with registered investors during the conference. Interested registered attendees can schedule meetings with Sensus Healthcare management through their ROTH representative or by contacting Tirth Patel at Alliance Advisors.
Sensus Healthcare (NASDAQ: SRTS) announces its participation in the 2025 American Academy of Dermatology Annual Meeting, showcasing its commercial and pre-commercial products at Booth #2451. The company will present its full line of Superficial Radiotherapy (SRT) systems, including the SRT-100®, SRT-100+, and SRT-100 Vision™.
The exhibition will feature 'The A.I. Experience,' highlighting new innovations including a prototype handheld ultrasound device for skin lesion identification and the TransDermal Infusion (TDI) product with Sentinel™ IT Solutions. The TDI system, pending regulatory approval, will enable platelet-rich plasma application for hair restoration and has shown potential applications for hyperhidrosis treatment.
The event will take place March 7-11, 2025, at the Orange County Convention Center in Orlando, Florida, featuring over 350 exhibitors and expecting nearly 20,000 attendees.
Sensus Healthcare (NASDAQ: SRTS) has announced the publication of a significant study in the Annals of Plastic Surgery demonstrating the effectiveness of their SRT-100® system in preventing keloid recurrence. The study, conducted at Tri Service Military Hospital in Taiwan, evaluated the combination of surgical keloid excision with primary wound closure followed by Superficial Radiation Therapy (SRT).
The research, involving 12 patients with 16 keloids, showed no keloid recurrence in most patients during follow-up periods exceeding six months. This marks Sensus Healthcare's first study in Asia, with the hospital utilizing the SRT-100® since 2023.
The study's results are particularly significant as keloids, which are benign skin tumors caused by abnormal scar tissue growth, traditionally show high recurrence rates with conventional treatments like corticosteroid injections, cryotherapy, and laser therapy. The integration of SRT targets excess fibroblast activity, addressing the root cause of keloid regrowth.
Sensus Healthcare (NASDAQ: SRTS) has announced the resumption of its share repurchase program, allowing for the purchase of up to $3.0 million of common stock in open-market transactions. The program, initially approved by the Board of Directors in August 2023, has already seen the repurchase of 9,427 shares.
CEO Joe Sardano stated that the company views the current stock price as a compelling opportunity for repurchases, expressing confidence in growth prospects. The company successfully completed a similar $3 million repurchase program in 2022.
The timing and volume of share repurchases will be determined by management based on capital needs, stock price, and market conditions. The program may include open-market purchases, block trades, and exchange transactions, with the flexibility to suspend or discontinue at any time.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q4 and full-year 2024 results, marking its fifth consecutive quarter of profitability. Q4 revenues reached $13.1 million with net income of $1.5 million ($0.09 per diluted share). The company achieved record shipments of 39 SRT systems in Q4 and 115 systems for the full year, representing increases of 18% and 74% respectively.
Full-year 2024 revenues grew 71% to $41.8 million, with net income of $6.6 million ($0.41 per diluted share). The company maintains a strong financial position with $22.1 million in cash and no debt. Management expects Q1 2025 sales to be lower than Q1 2024, though anticipating full-year growth. The company continues to expand its Fair Deal Agreement program and plans to re-submit its TDI 510(k) application in H1 2025.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its upcoming participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, in Atlantic City, N.J.
The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 2:00 PM Eastern Time in Studio 2 of the Borgata Hotel Casino & Spa. During the conference, management will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has scheduled its 2024 fourth quarter and full year financial results announcement for Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. Eastern time to discuss results and provide a business update.
Participants can pre-register for the call through a provided link for a unique dial-in number, or join by dialing 844-481-2811 (U.S./Canada) or 412-317-0676 (International). The call will be webcast live and available for replay until March 5th, with replay numbers provided for U.S., Canada, and International callers.
Sensus Healthcare (NASDAQ: SRTS) has partnered with Pompano Veterinary Oncology to pioneer mobile superficial radiotherapy (SRT) treatment for companion animals in South Florida. The veterinary practice has purchased an SRT-100™ system to provide treatments via a mobile van, both for home visits and veterinary clinics.
This marks the fourth SRT system being used for animal treatment, with two systems at Colorado State University School of Veterinary Medicine and one at Beit Veri College in Tel Aviv. The mobile service will complement Pompano Veterinary Oncology's existing treatments, including chemotherapy, immunotherapy, surgery, and tumor-specific electroporation therapy.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q3 2024 financial results with revenues reaching $8.8 million, a 127% increase from $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) compared to a net loss of $1.5 million in the prior year. Key highlights include shipping 27 systems, entering seven new Fair Deal Agreements for SRT-100 Vision units, and maintaining a strong balance sheet with $22.6 million in cash and no debt. The company expects to have over 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by year-end.
Sensus Healthcare (SRTS) reported strong Q3 2024 financial results with revenues more than doubling to $8.8 million compared to $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) versus a net loss of $1.5 million in the prior year. They shipped 27 systems during the quarter and signed a significant Fair Deal Agreement with Platinum Dermatology, a network of 130 dermatology clinics. The company maintained a strong financial position with $22.6 million in cash and no debt. Gross profit margin improved to 59.3% from 51.0% year-over-year.
